Avadel Pharmaceuticals (AVDL) Receivables: 2009-2020
Historic Receivables for Avadel Pharmaceuticals (AVDL) over the last 9 years, with Jun 2020 value amounting to $7.3 million.
- Avadel Pharmaceuticals' Receivables fell 55.03% to $7.3 million in Q2 2020 from the same period last year, while for Jun 2020 it was $40.7 million, marking a year-over-year decrease of 39.80%. This contributed to the annual value of $10.1 million for FY2019, which is 42.47% down from last year.
- According to the latest figures from Q2 2020, Avadel Pharmaceuticals' Receivables is $7.3 million, which was down 17.51% from $8.8 million recorded in Q1 2020.
- Avadel Pharmaceuticals' Receivables' 5-year high stood at $24.1 million during Q3 2017, with a 5-year trough of $4.9 million in Q1 2016.
- Over the past 3 years, Avadel Pharmaceuticals' median Receivables value was $16.1 million (recorded in 2018), while the average stood at $14.6 million.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Receivables skyrocketed by 176.73% in 2017, and later crashed by 55.03% in 2020.
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Receivables stood at $17.8 million in 2016, then fell by 17.12% to $14.8 million in 2017, then grew by 18.78% to $17.6 million in 2018, then crashed by 42.47% to $10.1 million in 2019, then plummeted by 55.03% to $7.3 million in 2020.
- Its Receivables stands at $7.3 million for Q2 2020, versus $8.8 million for Q1 2020 and $10.1 million for Q4 2019.